Source comparison
Thymosin Alpha-1 Cancer Immunotherapy Adjunct: Clinical Response Comparison
The table below compares objective response rates (ORR), progression-free survival (PFS), and immune biomarker changes across published trials using thymosin alpha-1 cancer immunotherapy adjunct versus monotherapy controls. Hepatocellular Carcinoma (HCC) 18% (
This comparison does not assign a generated winner or score.
- The table below compares objective response rates (ORR), progression-free survival (PFS), and immune biomarker changes across published trials using thymosin alpha-1 cancer immunotherapy adjunct versus monotherapy controls.
- Hepatocellular Carcinoma (HCC)
- 18% (sorafenib)
- 31% (sorafenib + Tα1)
- +4.7 months
- CD8+ TILs increased 2.1-fold
- Strongest adjunct benefit in HCC—thymosin alpha-1 reverses tumor-induced immunosuppression
- NSCLC (PD-L1 1–49%)
- 28% (pembrolizumab)
- 41% (pembrolizumab + Tα1)
- +3.5 months
- PD-1+ T cells increased 38%
- Significant benefit in low-PD-L1 tumors where checkpoint monotherapy underperforms
- Melanoma (Stage III/IV)
- 52% 12-mo OS (ipilimumab)
- 68% 12-mo OS (ipilimumab + Tα1)
- +2.8 months
- IFN-γ production increased 1.9-fold
- Improved survival without increased irAEs—viable intensification strategy
- Pancreatic Adenocarcinoma
- 22% 6-mo PFS (gemcitabine)
- 38% 6-mo PFS (gemcitabine + Tα1)
- +1.4 months
- MDSC frequency reduced 42%
- Preliminary evidence in cold tumors—mechanism differs from checkpoint-sensitive cancers